Literature DB >> 11824658

Detection of ophthalmoscopically occult maculopathy by focal electroretinography.

E T Schmeisser1, A D Epstein.   

Abstract

We performed focal electroretinography (FERG) in 10 patients with reduced vision of unknown cause. No patient gave a family history of uncorrectably reduced vision, and none had taken any drug known to damage the retina. Visual acuity claims ranged from 20/40 to finger counting. Color discrimination was reduced in all but one patient. Visual field sensitivity was reduced nonspecifically in five of the six patients who could perform perimetry reliably. Ophthalmoscopy showed no pertinent abnormality in four of 10 patients, mildly reduced foveal reflex in two of 10, arteriolar narrowing in two of 10, foveal pigment disturbance in one of 10, and preretinal gliosis in one of 10. Flash visual evoked potential (VEP) testing showed no abnormality in seven of 7 patients. The pattern VEP was reduced or delayed in five of 5 patients, only one of whom showed the expected amplitude loss with decreasing check size. Five patients completed full-field electroretinography, six patients completed fluorescein angiography, and none showed pertinent abnormality on either test. FERG was performed in both eyes of seven patients and in one eye of three others. Signals were non-recordable from four eyes, abnormal in nine, equivocal in three, and normal in one. The severity of FERG abnormality did not correlate with the severity of acuity loss. FERG abnormalities were found in fourteen of 17 eyes of 10 patients with vision loss out of proportion to clinical findings. In these patients only one of 5 pattern VEP tests, none of 5 full-field ERGs, and none of 7 fluorescein angiograms suggested correspondingly severe maculopathy. The FERG results in these cases mitigated suspicions of nonorganic vision loss and permitted speedier referral to retinal disease and low vision specialists.

Entities:  

Mesh:

Year:  2001        PMID: 11824658     DOI: 10.1023/a:1013003212521

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  8 in total

1.  Foveal cone electroretinograms in patients with central visual loss of unexplained etiology.

Authors:  G P Matthews; M A Sandberg; E L Berson
Journal:  Arch Ophthalmol       Date:  1992-11

2.  Visual conversion reaction in children. II. Follow-up.

Authors:  R T Rada; A E Krill; G G Meyer; D Armstrong
Journal:  Psychosomatics       Date:  1973 Sep-Oct       Impact factor: 2.386

3.  A follow-up of patients diagnosed as suffering from "hysteria".

Authors:  E T Slater; E Glithero
Journal:  J Psychosom Res       Date:  1965-09       Impact factor: 3.006

4.  Foveal electroretinogram as a clinical test.

Authors:  G B Arden; J L Bankes
Journal:  Br J Ophthalmol       Date:  1966-12       Impact factor: 4.638

5.  Focal cone electroretinograms: aging and macular disease.

Authors:  D G Birch; G E Fish
Journal:  Doc Ophthalmol       Date:  1988-07       Impact factor: 2.379

6.  A comparison of visual function tests in eyes with maculopathy.

Authors:  G E Fish; D G Birch; D G Fuller; R Straach
Journal:  Ophthalmology       Date:  1986-09       Impact factor: 12.079

7.  Hereditary macular dystrophy without visible fundus abnormality.

Authors:  Y Miyake; K Ichikawa; Y Shiose; Y Kawase
Journal:  Am J Ophthalmol       Date:  1989-09-15       Impact factor: 5.258

8.  Foveal cone electroretinograms in retinitis pigmentosa and juvenile maular degeneration.

Authors:  M A Sandberg; S G Jacobson; E L Berson
Journal:  Am J Ophthalmol       Date:  1979-10       Impact factor: 5.258

  8 in total
  2 in total

1.  A case of unilateral occult maculopathy with normal-tension glaucoma.

Authors:  Kazuki Hotta
Journal:  Jpn J Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 2.447

2.  Flash electroretinography: normative values with surface skin electrodes and no pupil dilation using a standard stimulation protocol.

Authors:  Eleftherios S Papathanasiou; Savvas S Papacostas
Journal:  Doc Ophthalmol       Date:  2007-07-04       Impact factor: 2.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.